CHINA STudy of Exforge (valsartan/amlodipine single-pill combination)-bAsed long-Term blood pressUre management in hypertenSive patients (CHINA STATUS III)

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900021324

Enrollment

Unknown

Registered

2019-02-15

Start date

2013-07-05

Completion date

Unknown

Last updated

2019-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Case series:Exforge treatment

Eligibility

Sex/Gender

All

Age

30 Years to 92 Years

Inclusion criteria

Inclusion criteria: 1. Male or female patients aged = 18 with essential hypertension; 2. Patients who have received Exforge treatment for at least 4 weeks; 3. Patients who have signed the ICF.

Exclusion criteria

Exclusion criteria: 1. Patients contraindicated for Exforge use according to the label; 2. Pregnant and lactating women, or fertile women who have not taken proper contraceptive measures; 3. Patients judged by the investigator to be not appropriate to take Exforge.

Design outcomes

Primary

Measure	Time frame
BP Control Rate;Compliance;	—

Secondary

Measure	Time frame
24 Abpm;Hbpm;	—

Countries

China

Contacts

Public ContactYong Huo

Peking University First Hospital

huoyong@263.net.cn+86 13901333060

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 21, 2026